Skip to main content

DIMA Biotech

DIMA_Biotech

DIMA Biotechnology Ltd. is a biotech company focusing on preclinical R&D products and services for druggable targets. They plan to complete the preparation of lead antibody molecules for all druggable targets in the next 3-5 years. DIMA Biotech provides multiple pre-prepared lead antibody molecules for each target to help pharmaceutical companies skip the tedious steps of monoclonal antibody platform establishment and lead molecule screening. Therefore,  companies can  have more time to focus on the biological mechanism and developability study of drug targets, thus accelerating the process of new drug R&D.

Over the years, DIMA Biotech has been deeply engaged in developing and optimizing the underlying technology platforms for preclinical research. Currently, they have established two independently developed core technology platforms:

Single/multiple transmembrane protein eukaryotic expression, preparation and purification platforms, apply mammalian cell expression systems, provide ECD or full-length membrane protein products closest to native conformation and functional validation. In addition, DIMA Biotech has developed five major functional full-length transmembrane protein preparation systems, including Membrane Nanoparticle (MNP), Virus-Like Particle (VLP), Exosome (EXO), Detergent and Synthetic Nanodisc. Thousands of drug target protein products are in stock. 
DimAb® High-throughput single B-cell lead antibody molecule discovery platform. DIMA Biotech has completed the preparation and screening of lead antibody molecules against more than 200 drug targets by this platform in just two years. Moreover, they have formed strategic partnerships with several international pharmaceutical enterprises and licensed several drug target molecules. DIMA’s preclinical development strength is widely recognized by the industry. 


www.dimabio.com

The prices are on request! Contact Us by e-mail info@sobekbio.com

Starter Bio

starter_bio

STARTER Bio is a professional IVD core materials provider. STARTER Bio’s recombinant proteins, antibodies and other materials have been applied widely in the world. STARTER Bio is dedicated to developing and delivering highly competitive antibodies and proteins for IVD assay development and research applications. With extensive knowledge on core materials development and in-vitro diagnostic assays development, The company's core team has been deeply engaged in antibody research and development for nearly 20 years.
Their products cover many fields, including infectious diseases, tumor biomarkers, cardiac markers, inflammation biomarkers and hormone markers. Those products are applied extensively in top IVD manufacturers in China, US, Japan, EU and other areas.

With the mission of accelerating the diagnosis of human and animal diseases and escorting human and animal health, the company is based on solid science and technology, adhering to the values of integrity and honesty, guided by the needs of industry customers, and is willing to cooperate sincerely with fraternity around the world, Open a new chapter in health.

www.starter-bio.com

The prices are on request! Contact Us by e-mail info@sobekbio.com

Human IL15 Protein, hFc Tag PME100882

PICTO_DIMABiotech.jpg


The add to cart button will appear once you select the values above

Specifications

10µg / 50µg / 100µg

Alternative names:

IL-15;Interleukin 15;MGC9721

Description:

Recombinant Human IL15 Protein with C-terminal human Fc tag

Background:

The protein encoded by this gene is a cytokine that regulates T and natural killer cell activation and proliferation. This cytokine and interleukine 2 share many biological activities. They are found to bind common hematopoietin receptor subunits, and may compete for the same receptor, and thus negatively regulate each other's activity. The number of CD8 memory cells is shown to be controlled by a balance between this cytokine and IL2. This cytokine induces the activation of JAK kinases, as well as the phosphorylation and activation of transcription activators STAT3, STAT5, and STAT6. Studies of the mouse counterpart suggested that this cytokine may increase the expression of apoptosis inhibitor BCL2L1/BCL-x(L), possibly through the transcription activation activity of STAT6, and thus prevent apoptosis. Alternatively spliced transcript variants of this gene have been reported. [provided by RefSeq, Feb 2011]

Molecular characterization:

IL15(Asn49-Ser162) hFc(Glu99-Ala330)

Molecular weight:

The protein has a predicted molecular mass of 38.9 kDa after removal of the signal peptide. The apparent molecular mass of IL15-hFc is approximately 35-55kDa due to glycosylation.

Tag:

C-Human Fc Tag

Expression host:

HEK293

Target:

IL15

Purity:

The purity of the protein is greater than 95% as determined by SDS-PAGE and Coomassie blue staining.

Formulation / Reconstitution:

Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.

Storage:

Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.

More info:

Email info@sobekbio.com

Orders:

Email orders@sobekbio.com